NCT07204977View on ClinicalTrials.gov

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Amyotrophic Lateral SclerosisMotor Neuron Disease
Interventions
DRUG

Acamprosate calcium

tablet

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT07204977 - Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) | Biotech Hunter | Biotech Hunter